Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LY2510924 + sunitinib
- Development stage
- Discontinued
- Lead developer
- Eli Lilly
- Modality
- Small Molecules, Peptides
- Administration
- Subcutaneous, Oral
01
Overview
LY2510924 + sunitinib is an investigational combination therapy consisting of **LY2510924**, a potent, selective peptide antagonist of the chemokine receptor CXCR4, and **sunitinib**, a small molecule multitargeted tyrosine kinase inhibitor. LY2510924 inhibits the CXCR4/stromal cell-derived factor-1 (SDF-1) axis, which is implicated in tumor growth, metastasis, and chemoresistance. Sunitinib targets several receptor tyrosine kinases, including vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors (PDGFRs), KIT, and FLT3, among others, inhibiting angiogenesis and tumor proliferation. The combination was primarily studied as first-line therapy for metastatic renal cell carcinoma (RCC), with the rationale that dual inhibition may enhance antitumor activity through disruption of both tumor cell migration and angiogenesis[4][6].
- Other names
- SUN
02
Targets
CXCR4 (C-X-C motif chemokine receptor 4)KIT (c-KIT proto-oncogene receptor tyrosine kinase)FLT3 (Fms related receptor tyrosine kinase 3)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on LY2510924 + sunitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LY2510924 + sunitinib.